Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer says Monsanto...

    Bayer says Monsanto India integration to complete in one year

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-09-24T09:00:39+05:30  |  Updated On 24 Sept 2018 9:00 AM IST
    Bayer says Monsanto India integration to complete in one year


    Bayer completed the USD 63 billion mega-deal to acquire US-based Monsanto to create the world's biggest agrochemical and seed company.




    New Delhi: It will take at least one year to complete the integration of Monsanto India into the Bayer Group, a senior official of German pharma and chemical major has said.

    In June this year, Bayer completed the USD 63 billion mega-deal to acquire US-based Monsanto to create the world's biggest agrochemical and seed company. The acquisition of Monsanto has been completed globally but it is still in process in India.

    "We just started three weeks ago to integrate the two companies. The integration of two companies in India will take some time. Since the two companies are listed entities, it is going to take legally quiet some time. I would say, from a legal entity point of view, one year," Bayer Crop Science division president Liam Condon told in an interview.

    The integration of the staff personnel of the two listed companies will start immediately with teams getting together and sharing knowledge and information about customers, he said.

    But the full integration and seamless operation as one company would take a couple of years in India, he said adding that for its customers it would start working as one team sooner.

    Condon is also a member of the board of management of Bayer AG.

    Already, a business restructuring sub-committee has been constituted to evaluate the proposal relating to the integration of the Monsanto India and Bayer's Indian subsidiary Bayer CropScience Ltd.

    In India, both entities have a presence in the production and sale of vegetable seeds, cotton seeds as well as in production and sale of non-selective herbicides.

    Monsanto has been selling genetically modified (GM) cotton seeds in India for more than a decade through its joint venture Mahyco Monsanto Biotech that has sub-licensed Bt cotton seed technology to various domestic seed companies.

    However, the company is now involved in a legal case where it has appealed against the Indian government's decision to fix cotton price along with trait value (royalty) under the Cotton Seed Price Control Order.

    Separately, it is fighting a legal case with Indian firm Nuziveedu Seeds over the patent right of its technology.






    BayerBt cotton seedCondoncotton seedsgenetically modifiedMahyco Monsanto BiotechMonsantoNuziveeduNuziveedu SeedsUS-based Monsanto
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok